Successful Treatment of HER2 V659E Mutation-Positive Lung Adenocarcinoma With Trastuzumab Deruxtecan: A Case Report.

IF 2.3 3区医学 Q3 ONCOLOGY

Thoracic Cancer Pub Date : 2025-06-01 DOI:10.1111/1759-7714.70100

Mariko Nishihara, Yuki Shinno, Yoshihiro Masui, Ken Masuda, Yuji Matsumoto, Yusuke Okuma, Tatsuya Yoshida, Yasushi Goto, Hidehito Horinouchi, Noboru Yamamoto, Yuichiro Ohe

引用次数: 0

Abstract

A 67-year-old patient with metastatic lung adenocarcinoma harboring a HER2 V659E mutation received trastuzumab deruxtecan (T-DXd) as second-line treatment. The V659E mutation is a rare alteration located in the transmembrane domain of HER2. The antitumor effect observed in this patient was comparable to that reported in a previous phase 2 trial, in which most patients had mutations in the kinase domain. Here, we present the detailed clinical course and discuss the findings from a molecular biological perspective.

查看原文本刊更多论文

曲妥珠单抗治疗HER2 V659E突变阳性肺腺癌1例报告

一名携带HER2 V659E突变的67岁转移性肺腺癌患者接受了曲妥珠单抗德鲁西替康（T-DXd）作为二线治疗。V659E突变是位于HER2跨膜结构域的罕见突变。在该患者中观察到的抗肿瘤效果与之前的2期试验中报道的效果相当，在2期试验中，大多数患者在激酶结构域发生突变。在这里，我们介绍详细的临床过程，并从分子生物学的角度讨论结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Thoracic Cancer ONCOLOGY-RESPIRATORY SYSTEM

CiteScore

5.20

自引率

3.40%

发文量

439

审稿时长

2 months

期刊介绍： Thoracic Cancer aims to facilitate international collaboration and exchange of comprehensive and cutting-edge information on basic, translational, and applied clinical research in lung cancer, esophageal cancer, mediastinal cancer, breast cancer and other thoracic malignancies. Prevention, treatment and research relevant to Asia-Pacific is a focus area, but submissions from all regions are welcomed. The editors encourage contributions relevant to prevention, general thoracic surgery, medical oncology, radiology, radiation medicine, pathology, basic cancer research, as well as epidemiological and translational studies in thoracic cancer. Thoracic Cancer is the official publication of the Chinese Society of Lung Cancer, International Chinese Society of Thoracic Surgery and is endorsed by the Korean Association for the Study of Lung Cancer and the Hong Kong Cancer Therapy Society. The Journal publishes a range of article types including: Editorials, Invited Reviews, Mini Reviews, Original Articles, Clinical Guidelines, Technological Notes, Imaging in thoracic cancer, Meeting Reports, Case Reports, Letters to the Editor, Commentaries, and Brief Reports.